Copyright ©The Author(s) 2017.
World J Hematol. Feb 6, 2017; 6(1): 1-10
Published online Feb 6, 2017. doi: 10.5315/wjh.v6.i1.1
Table 3 Patients characteristics
PatientSexAge at ASCT (yr)Disease phase at ASCTTime from diagnosis to ASCT (mo)Indication for ASCTDonor sex
1M221st AP50Resistance to imatinib and clonal evolutionM
2F512nd CP14Previous myeloid blastic phaseM
3M252nd CP61Previous lymphoid blastic phaseM
4M331st CP37Resistance to imatinib and dasatinibM
5F541st AP103Resistance to imatinib, nilotinib and dasatinib 1st accelerated phaseF
6M651st CP133Resistance to imatinib and nilotinibF
7F491st CP62Resistance to imatinibM
8M532nd CP63Previous myeloid blastic phaseM
9M411st CP51Resistance to imatinibM
10M611st CP75Resistance to imatinib, nilotinib and dasatinibF